Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 255

recruiting
3 970
countries
28
conditions
2 124

10 522 trials match your criteria

Safety Study of (+)-α-Dihydrotetrabenazine for Patients with Moderate to Severe Tardive Dyskinesia

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:NBI-98782

Study on the Effectiveness of Clopidogrel, Prasugrel, and Ticagrelor in Patients with Coronary Acute Syndrome Using VerifyNow Device

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Clopidogrel

Study on the Safety and Tolerability of STK-002 for Patients with Autosomal Dominant Optic Atrophy

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:STK-002

Study on Nitrous Oxide and Oxygen for Treating Depression in Nursing Home Residents with Neurocognitive Disorders

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Nitrogen

Study on the Effects of Rilvegostomig and Drug Combination for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:AZD0901

Glioblastoma

Recruiting

Study on Lomustine and Temozolomide for Newly Diagnosed Glioblastoma Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Temozolomide

Study on Low-Dose Aldesleukin for Patients with Pemphigus, Mucous Membrane Pemphigoid, Polymyositis, Dermatomyositis, and Primary Sclerosing Cholangitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin

Study on the Safety and Effectiveness of Lufepirsen Gel for Patients with Persistent Corneal Epithelial Defects

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lufepirsen

Study on the Safety and Effectiveness of Baricitinib for Children Aged 1 to 17 with Juvenile Idiopathic Arthritis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Baricitinib

Glioblastoma

Recruiting

Study on Glioblastoma Treatment with Olaptesed Pegol and Radiation, with Bevacizumab or Pembrolizumab, for Patients with Unmethylated MGMT Promoter

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Breast cancer

Recruiting

Study of Tuvusertib and Fulvestrant for Advanced Breast Cancer Resistant to CDK4/6 and Aromatase Inhibitors in Hormone Receptor-Positive, HER2-Negative Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant

Neoplasm

Recruiting

Study on the Safety and Tolerability of D3S-001 Alone or with Drug Combination in Adults with Advanced Solid Tumors with KRAS p.G12C Mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.